Loading, Please Wait...
ARCHAMPS, France, July 22, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced that the World Health Organization (WHO) has recommended setanaxib as the international nonproprietary name (INN) for GKT831.
The new stem “naxib" approved by WHO refers to NADPH oxidase inhibitors, and formally establishes a new therapeutic class under the WHO INN system.
The WHO assigns an INN to new pharmaceutical substances or active pharmaceutical ingredients (API). Each INN includes a stem which indicates that a pharmaceutical product belongs to a group of substances having similar pharmacological activity, and a new stem is only recommended when a group of at least several new substances shows a confirmed novel mode of action.
Elias Papatheodorou, CEO of Genkyotex, commented: “A s the leader in the development of NOX therapeutics, we are thrilled with the WHO decision to formalize NOX inhibitors as a novel therapeutic class. By recommending the INN setanaxib for GKT831, the most advanced compound in the NOX inhibitor class, the WHO is recognizing its novel mechanism of action.”
NOX inhibitors have a significant therapeutic potential for fibrotic and inflammatory disorders, neurodegenerative diseases, and oncology. Recently, GKT831 has shown clinical evidence of anti-inflammatory and anti-fibrotic activity in patients with fibrotic liver disease in a Phase 2 Primary Biliary Cholangitis (PBC) trial, highlighting its potential as a possible treatment for multiple complex and difficult to treat fibrotic disorders, including non-alcoholic steatohepatitis (NASH), PBC, diabetic kidney disease (DKD), and idiopathic pulmonary fibrosis (IPF).
A second Phase 2 study is ongoing in diabetic patients with kidney fibrosis, and the US Food and Drug Administration (FDA) recently approved the initiation of an additional Phase 2 trial in patients with patients with IPF.
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. Its unique platform enables the identification of orally available small-molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor has shown evidence of anti-fibrotic activity in a Phase II clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and Genkyotex is planning to initiate a Phase III clinical trial in PBC following its positive Phase II results. GKT831 is also being evaluated in an investigator-initiated Phase II clinical trial in Type 1 Diabetes and Kidney Disease (DKD). A grant from the United States National Institutes of Health (NIH) of $8.9 million was awarded to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs, the core component of the program will be to conduct a Phase 2 trial with the GKT831 in patients with IPF. This product candidate may also be active in other fibrotic indications.
Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Private Ltd (Serum Institute), the world’s largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases.
For further information, please go to www.genkyotex.com .
This press release may contain forward-looking statements by the company with respect to its objectives. Such statements are based upon the current beliefs, estimates and expectations of Genkyotex’s management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release and actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include uncertainties involved in the development of Genkyotex’s products, which may not succeed, or in the delivery of Genkyotex’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect Genkyotex’s capacity to commercialize the products it develops. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document (document de référence) registered by the French Financial Markets Authority (the AMF) on 26 April 2019 under number R.19-014, and those linked to changes in economic conditions, the financial markets, or the markets on which Genkyotex is present. Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.
|Media relations||Investor relations|
+33 6 2774 74 49
LifeSci Advisors, LCC
+1 212 915 2578